Welcome to our dedicated page for Firefly Neuroscience news (Ticker: AIFF), a resource for investors and traders seeking the latest updates and insights on Firefly Neuroscience stock.
Firefly Neuroscience, Inc. develops AI-enabled precision neuroscience tools built around EEG/ERP brain data, including its FDA 510(k)-cleared brain analytics technology, the BNA platform, the Evoke System and the CLEAR Platform. News about AIFF centers on commercialization of cognitive electrophysiology analytics, growth in brain scan volumes, expansion of its standardized EEG/ERP data repository, and the use of NVIDIA GPU acceleration for signal processing and biomarker discovery.
Recurring company updates also cover research applications in neurological and mental health conditions such as ADHD, depression, dementia, anxiety disorders, concussions and cognitive disorders; partnerships with clinics, researchers and institutional customers; integration of Evoke Neuroscience; and periodic financial results tied to equipment sales, rentals, per-use fees and services for projects or clinical studies.
Firefly Neuroscience (NASDAQ: AIFF) reported discovery of a novel electrophysiological biomarker for PTSD using its FDA-510(k)-cleared Evoke System. The finding stems partly from its public-private partnership with the U.S. Department of War to support assessment and treatment of active-duty service members and veterans.
The biomarker, identified via deep-learning analysis of EEG and ERP data on NVIDIA L40S GPU infrastructure, may support PTSD diagnostics and treatment decisions. Firefly sees potential applications across defense health, pharmaceutical clinical trials, and clinical psychiatry, aligning with its goal to build an EEG/ERP-based brain foundation model.
Firefly (NASDAQ: AIFF) announced it has surpassed 200,000 standardized EEG/ERP brain scans, driven by organic growth and the May 2025 acquisition of Evoke Neuroscience. Sequential scan volumes grew 5%, 11%, 15%, and 17% in the last four quarters, and the company cites NVIDIA L40S GPU acceleration to boost AI biomarker discovery.
This milestone supports Firefly’s stated goal of building and launching the world’s first EEG/ERP-based foundation model of the human brain.
Firefly (NASDAQ: AIFF) announced a public-private partnership with the Department of War on March 26, 2026, to deploy its FDA 510(k)-cleared, AI-powered EEG/ERP platform for assessment and treatment of PTSD and TBI in U.S. service members and veterans.
The deal expands Firefly’s commercial footprint into U.S. government and defense health sectors, builds on the May 2025 Evoke acquisition, and cites large military health burdens to justify deployment.
Firefly Neuroscience (NASDAQ: AIFF) announced a research advance on March 13, 2026: its AI-powered EEG/ERP platform using data from its FDA 510(k)-cleared Evoke System may help distinguish the three main ADHD subtypes.
The company cites a growing foundation model trained on over 191,000 brain scans, potential clinical uses for subtype-specific treatment guidance and monitoring, and access to NVIDIA GPU acceleration to speed EEG/ERP processing.
Firefly (NASDAQ: AIFF) reported a >20-fold expansion of its commercial footprint and a 33-fold increase in EEG/ERP scan volumes, ending 2025 with 99 commercial users and more than 10,800 EEG/ERP brain scans.
The company cited its acquisition of Evoke Neuroscience and deployment of NVIDIA L40S GPU acceleration as enablers for AI-driven biomarker discovery and progress toward an EEG/ERP-based foundation model of the human brain.
Firefly Neuroscience (NASDAQ: AIFF) reported Q3 2025 results showing significant integration benefits from its May 2025 acquisition of Evoke. Q3 revenue was $388,000, up from $33,000 year‑over‑year and +30% sequentially. EEG/ERP scan volumes rose 10.9% sequentially. Total operating expenses fell ~35% versus Q3 2024 to ~$2.8 million, helping reduce Q3 net loss to ~$2.6 million (‑38% year‑over‑year). Cash used in operations was ~$1.5 million (lowest quarter in first nine months of 2025) and the company ended the quarter with $4.3 million cash. The company also highlighted new CLEAR preprocessing technology and strategic partnerships advancing its EEG/ERP offerings.
Firefly Neuroscience (NASDAQ: AIFF) has announced a strategic partnership with HealingMaps and Advanced Behavioral Strategies to provide EEG-based cognitive analytics to over 2,500 specialized clinics across North America. The collaboration follows HealingMaps' launch of the Healing Health Alliance, a pioneering Group Purchasing Organization for alternative therapy clinics.
The partnership will integrate Firefly's FDA-510(k)-cleared brain health analytics platform, which uses AI and EEG technology to provide objective assessments, replacing traditional subjective questionnaires. The platform analyzes brain activity using the world's largest normative EEG/ERP database, offering standardized insights for ketamine, psilocybin, and TMS treatments.
Firefly Neuroscience (NASDAQ: AIFF) has announced the successful deployment of its new 'CLEAR' (CLeaning EEG ARtifacts) Platform, powered by NVIDIA L40S GPU technology. The platform represents a significant advancement in EEG data preprocessing, achieving 60-80% faster processing times while maintaining high signal quality.
The CLEAR Platform utilizes state-of-the-art signal processing and machine learning techniques to clean EEG recordings from various artifacts, including muscle activity and environmental interference. This technology enhancement enables better detection of neural biomarkers crucial for neurological and psychiatric condition diagnosis and treatment.
This development follows Firefly's recent acceptance into the NVIDIA Connect Program and leverages the company's position as owner of the world's largest standardized EEG/ERP repository.
Firefly Neuroscience (NASDAQ: AIFF) has announced a new commercial agreement with the Institute of Human Genetics at Heidelberg University Hospital to utilize its FDA-cleared BNA™ Platform in a groundbreaking neuroscience study. The research focuses on investigating the neurophysiological impact of 15q13.3 copy number variants (CNVs).
The study involves analyzing EEG data from 30 subjects (15 with deletions and 15 with duplications) using Firefly's technology through 2026. The company will provide EEG systems, training, and analytical support, comparing results to its proprietary FDA-cleared normative database.
This collaboration builds on previous work between Firefly and Prof. Dr. med. Christian Schaaf, including a joint publication on CHRNA7-related phenotypes, and represents an important step in Firefly's commercial licensing strategy.